WA, November 18, 2015—Aminex Therapeutics, Inc., developer of a first-in-class
suppressor cell modulator cancer immunotherapy, today announced the addition of
Dr. Steven Weitman and Dr. Philippe Bey to its Scientific Advisory Board (SAB).
are very fortunate and delighted to have these two distinguished gentlemen join
our SAB,” stated Jim Skaggs, chief executive officer and chairman of Aminex
Therapeutics. “Both have enjoyed long, accomplished drug development careers
with extensive experience that is directly applicable to Aminex’s goal of
confirming its patented lead drug, AMX-513, in human clinical trials planned to
start in mid-2016.”
Bey was the designer and inventor of difluoromethylornithine (DFMO), one of the
two components of Aminex’s AMX-513 combination drug. He is currently senior
vice president of R&D at Thrasos Therapeutics, a private Canadian
clinical-stage biotechnology company.
Weitman is director of the Institute for Drug Development at the Cancer Therapy
and Research Center, an NCI-designated Cancer Center, at the University of
Texas Health Science Center at San Antonio. Dr. Weitman also worked with DFMO
in his early career and has been an advisor for neuroblastoma clinical trials
Bey and Weitman recently attended their first Aminex SAB meeting with Dr.
Michael Palfreyman, chairman of the SAB and Aminex’s senior VP of drug
development; existing SAB members Dr. Paul Schechter and Dr. Robert Lewis; and
Dr. Mark Burns, Aminex’s chief scientific officer and drug inventor. Drs.
Palfreyman and Schechter were also key players on the DFMO team 30 years ago,
and Dr. Burns developed Aminex’s AMX-513 drug combination. These six provide
the strong foundation of scientific capability and drug development experience
that guides Aminex’s plan and work, much of which is performed by an array of
highly experienced drug research consultants and contractors.
Additional information on the SAB members can
be found on Aminex’s website, referenced below.
About Aminex Therapeutics, Inc.
Therapeutics, Inc. is a drug development company focused on discovery,
development, and commercialization of suppressor cell modulators (SCMs), a new
class of small molecule cancer immunotherapies which enable the immune system
to attack cancer by regulating myeloid-derived suppressor cells. Aminex has extensively
demonstrated, in animal trials, the potential of its lead drug, AMX-513, to be
effective alone and to improve overall therapy when used in combination with
other cancer treatments. Aminex’s vision is to make significant treatment
contributions for a wide range of cancers and to ease rising costs of cancer
For more information, please visit www.aminextx.com.